268 related articles for article (PubMed ID: 22179399)
21. Prognostic effect of lymphocyte subgroup CD4+ and CD8+ cells in peripheral blood in renal transplant patients with cytomegalovirus viremia.
Chen JS; Li LS; Cheng DR; Ji SM; Sun QQ; Cheng Z; Wen JQ; Sha GZ; Liu ZH
Transplant Proc; 2009 Jun; 41(5):1639-42. PubMed ID: 19545698
[TBL] [Abstract][Full Text] [Related]
22. Monitoring of Cytomegalovirus (CMV)-Specific Cell-Mediated Immunity in Heart Transplant Recipients: Clinical Utility of the QuantiFERON-CMV Assay for Management of Posttransplant CMV Infection.
Chiereghin A; Potena L; Borgese L; Gibertoni D; Squarzoni D; Turello G; Petrisli E; Piccirilli G; Gabrielli L; Grigioni F; Lazzarotto T
J Clin Microbiol; 2018 Apr; 56(4):. PubMed ID: 29305542
[TBL] [Abstract][Full Text] [Related]
23. Timing of CMV-specific effector memory T cells predicts viral replication and survival after allogeneic hematopoietic stem cell transplantation.
Espigado I; de la Cruz-Vicente F; BenMarzouk-Hidalgo OJ; Gracia-Ahufinger I; Garcia-Lozano JR; Aguilar-Guisado M; Cisneros JM; Urbano-Ispizua A; Perez-Romero P
Transpl Int; 2014 Dec; 27(12):1253-62. PubMed ID: 25070273
[TBL] [Abstract][Full Text] [Related]
24. CMV-specific T-cell immunity in solid organ transplant recipients at low risk of CMV infection. Chronology and applicability in preemptive therapy.
Mena-Romo JD; Pérez Romero P; Martín-Gandul C; Gentil MÁ; Suárez-Artacho G; Lage E; Sánchez M; Cordero E
J Infect; 2017 Oct; 75(4):336-345. PubMed ID: 28599954
[TBL] [Abstract][Full Text] [Related]
25. Impact on the cytomegalovirus (CMV) viral load by CMV-specific T-cell immunity in recipients of allogeneic stem cell transplantation.
Avetisyan G; Larsson K; Aschan J; Nilsson C; Hassan M; Ljungman P
Bone Marrow Transplant; 2006 Nov; 38(10):687-92. PubMed ID: 17001346
[TBL] [Abstract][Full Text] [Related]
26. Immunological monitoring for guidance of preemptive antiviral therapy for active cytomegalovirus infection in allogeneic stem-cell transplant recipients: a pilot experience.
Solano C; Benet I; Remigia MJ; de la Cámara R; Muñoz-Cobo B; Costa E; Clari MÁ; Bravo D; Amat P; Navarro D
Transplantation; 2011 Aug; 92(4):e17-20. PubMed ID: 21814124
[No Abstract] [Full Text] [Related]
27. Quantiferon-Cytomegalovirus assay: A potentially useful tool in the evaluation of CMV-specific CD8+ T-cell reconstitution in pediatric hematopoietic stem cell transplant patients.
Paouri B; Soldatou A; Petrakou E; Theodosaki M; Tsentidis C; Kaisari K; Oikonomopoulou C; Matsas M; Goussetis E
Pediatr Transplant; 2018 Aug; 22(5):e13220. PubMed ID: 29777573
[TBL] [Abstract][Full Text] [Related]
28. Effect of cytomegalovirus viremia on subclinical rejection or interstitial fibrosis and tubular atrophy in protocol biopsy at 3 months in renal allograft recipients managed by preemptive therapy or antiviral prophylaxis.
Reischig T; Jindra P; Hes O; Bouda M; Kormunda S; Treska V
Transplantation; 2009 Feb; 87(3):436-44. PubMed ID: 19202451
[TBL] [Abstract][Full Text] [Related]
29. [Clinical study of low cytomegalovirus viral load thresholds for preemptive antiviral therapy in hematopoietic cell transplant recipients].
Li L; Wang Y; Yan CH; Huang XJ
Zhonghua Nei Ke Za Zhi; 2018 Mar; 57(3):191-195. PubMed ID: 29518863
[No Abstract] [Full Text] [Related]
30. Cell-mediated immunity to predict cytomegalovirus disease in high-risk solid organ transplant recipients.
Kumar D; Chernenko S; Moussa G; Cobos I; Manuel O; Preiksaitis J; Venkataraman S; Humar A
Am J Transplant; 2009 May; 9(5):1214-22. PubMed ID: 19422346
[TBL] [Abstract][Full Text] [Related]
31. Human cytomegalovirus end-organ disease is associated with high or low systemic viral load in preemptively treated solid-organ transplant recipients.
Gerna G; Lilleri D; Furione M; Castiglioni B; Meloni F; Rampino T; Agozzino M; Arbustini E
New Microbiol; 2012 Jul; 35(3):279-87. PubMed ID: 22842597
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of cytomegalovirus DNAaemia versus pp65-antigenaemia cutoff for guiding preemptive therapy in transplant recipients: a randomized study.
Gerna G; Baldanti F; Torsellini M; Minoli L; Viganò M; Oggionnis T; Rampino T; Castiglioni B; Goglio A; Colledan M; Mammana C; Nozza F; Daniele L;
Antivir Ther; 2007; 12(1):63-72. PubMed ID: 17503749
[TBL] [Abstract][Full Text] [Related]
33. Long-term renal graft function and survival in patients with high-risk for cytomegalovirus infection receiving preemptive therapy.
Alberú J; Morales-Buenrostro LE; Correa-Rotter R; Muñoz-Trejo T; Zúñiga-Varga J; Cuéllar-González JV; Mayorga-Madrigal H; Vanegas-Carrero R; Aranda F; Rodríguez-Romo R; Herrera-Garcia C; González-Michaca L; Sierra-Madero JG
Rev Invest Clin; 2008; 60(5):365-74. PubMed ID: 19227433
[TBL] [Abstract][Full Text] [Related]
34. Assessing the risk of CMV reactivation and reconstitution of antiviral immune response post bone marrow transplantation by the QuantiFERON-CMV-assay and real time PCR.
Krawczyk A; Ackermann J; Goitowski B; Trenschel R; Ditschkowski M; Timm J; Ottinger H; Beelen DW; Grüner N; Fiedler M
J Clin Virol; 2018; 99-100():61-66. PubMed ID: 29331844
[TBL] [Abstract][Full Text] [Related]
35. Cytomegalovirus-specific immunity and protection against viremia and disease in HIV-infected patients in the era of highly active antiretroviral therapy.
Weinberg A; Tierney C; Kendall MA; Bosch RJ; Patterson-Bartlett J; Erice A; Hirsch MS; Polsky B;
J Infect Dis; 2006 Feb; 193(4):488-93. PubMed ID: 16425127
[TBL] [Abstract][Full Text] [Related]
36. Utility of leflunomide in the treatment of complex cytomegalovirus syndromes.
Avery RK; Mossad SB; Poggio E; Lard M; Budev M; Bolwell B; Waldman WJ; Braun W; Mawhorter SD; Fatica R; Krishnamurthi V; Young JB; Shrestha R; Stephany B; Lurain N; Yen-Lieberman B
Transplantation; 2010 Aug; 90(4):419-26. PubMed ID: 20683281
[TBL] [Abstract][Full Text] [Related]
37. Cellular immune parameters associated with spontaneous control of CMV in children who underwent transplantation.
Guérin V; Dalle JH; Pédron B; Ouachée-Chardin M; Yakouben K; Baruchel A; Sterkers G
Bone Marrow Transplant; 2010 Mar; 45(3):442-9. PubMed ID: 19633694
[TBL] [Abstract][Full Text] [Related]
38. Therapeutic effect of the acquisition of cytomegalovirus-specific immune response during preemptive treatment.
Benmarzouk-Hidalgo OJ; Cisneros JM; Cordero E; Martín-Peña A; Sanchez B; Martin-Gandul C; Gentil MA; Gomez-Bravo MA; Lage E; Perez-Romero P
Transplantation; 2011 Apr; 91(8):927-33. PubMed ID: 21358366
[TBL] [Abstract][Full Text] [Related]
39. Dynamics of cytomegalovirus (CMV)-specific T cells in HIV-1-infected individuals progressing to AIDS with CMV end-organ disease.
Bronke C; Palmer NM; Jansen CA; Westerlaken GH; Polstra AM; Reiss P; Bakker M; Miedema F; Tesselaar K; van Baarle D
J Infect Dis; 2005 Mar; 191(6):873-80. PubMed ID: 15717261
[TBL] [Abstract][Full Text] [Related]
40. Specific Immunity to Cytomegalovirus in Pediatric Cardiac Transplantation.
Jacobsen MC; Manunta MDI; Pincott ES; Fenton M; Simpson GL; Klein NJ; Burch M
Transplantation; 2018 Sep; 102(9):1569-1575. PubMed ID: 29509573
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
